Effect of Cytotoxic T Lymphocytes Induced by Recombinant Adeno-Associated Virus on Different Hepatitis B Virus Genes

Authors Information
Article Notes and Dates
To Cite : Guicheng W, Xuan A, Yi X, Fang W, Lina X, et al. Effect of Cytotoxic T Lymphocytes Induced by Recombinant Adeno-Associated Virus on Different Hepatitis B Virus Genes, Hepat Mon. 2017 ;17(5):e42685. doi: 10.5812/hepatmon.42685.
Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63(1): 261-83[DOI][PubMed]
  • 2. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(4): 809-10[DOI][PubMed]
  • 3. Hagiwara S, Nishida N, Kudo M. Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World J Hepatol. 2015; 7(23): 2427-31[DOI][PubMed]
  • 4. Minami M. Future therapy for hepatitis B virus infection. Clin J Gastroenterol. 2015; 8(4): 167-71[DOI][PubMed]
  • 5. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, et al. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology. 2016; 150(3): 684-95[DOI][PubMed]
  • 6. Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol. 2016; 30: 93-105[DOI][PubMed]
  • 7. Kim D, Lyoo KS, Smith D, Hur W, Hong SW, Sung PS, et al. Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. J Med Virol. 2011; 83(12): 2082-7[DOI][PubMed]
  • 8. Moreau A, Vandamme C, Segovia M, Devaux M, Guilbaud M, Tilly G, et al. Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer. Mol Ther Methods Clin Dev. 2014; 1: 14028[DOI][PubMed]
  • 9. Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol. 2014; 92(2): 116-23[DOI][PubMed]
  • 10. Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL, et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother. 2007; 56(10): 1615-24[DOI][PubMed]
  • 11. You H, Liu Y, Cong M, Ping W, You C, Zhang D, et al. HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells. J Viral Hepat. 2006; 13(9): 605-12[DOI][PubMed]
  • 12. Liu Y, Chiriva-Internati M, You C, Luo R, You H, Prasad CK, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther. 2005; 12(3): 304-12[DOI][PubMed]
  • 13. van der Aa E, Buschow SI, Biesta PJ, Janssen HL, Woltman AM. The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function. PLoS One. 2016; 11(8): 161235[DOI][PubMed]
  • 14. Wei MJ, Pan XN, Wei KP, Li XH, Liu XL, Zhang XM, et al. Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection. Int Immunopharmacol. 2015; 27(2): 238-43[DOI][PubMed]
  • 15. Dai S, Zhuo M, Song L, Chen X, Yu Y, Zang G, et al. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice. Immunobiology. 2016; 221(7): 813-21[DOI][PubMed]
  • 16. Jing M, Wang J, Zhu S, Ao F, Wang L, Han T, et al. Development of a more efficient hepatitis B virus vaccine by targeting hepatitis B virus preS to dendritic cells. Vaccine. 2016; 34(4): 516-22[DOI][PubMed]
  • 17. Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol. 2015; 21(44): 12558-75[DOI][PubMed]
  • 18. Liu T, Song HL, Zheng WP, Shen ZY. Inhibition of HBV Replication in HepG2.2.15 Cells by Human Peripheral Blood Mononuclear Cell-Derived Dendritic Cells. Ann Clin Lab Sci. 2015; 45(5): 495-501[PubMed]
  • 19. Dai S, Zhuo M, Song L, Chen X, Yu Y, Tang Z, et al. Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo. Acta Biochim Biophys Sin (Shanghai). 2015; 47(11): 870-9[DOI][PubMed]
  • 20. Borges da Silva H, Fonseca R, Cassado Ados A, Machado de Salles E, de Menezes MN, Langhorne J, et al. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental blood-stage malaria. PLoS Pathog. 2015; 11(2): 1004598[DOI][PubMed]
  • 21. You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC. Oncoimmunology. 2012; 1(6): 847-55[DOI][PubMed]
  • 22. Gil-Farina I, Di Scala M, Vanrell L, Olague C, Vales A, High KA, et al. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression. PLoS One. 2013; 8(7): 67748[DOI][PubMed]
  • 23. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013; 20(4): 361-9[DOI][PubMed]
  • 24. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med. 2008; 10(7): 717-33[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check